Cytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy
Cytokinetics (Nasdaq: CYTK) announced on November 17, 2025 its support for a three-year American Heart Association initiative to improve diagnosis, access, and treatment for people living with hypertrophic cardiomyopathy (HCM).
The company said it will back efforts to expand participation in a national HCM Registry powered by Get With The Guidelines®, broaden certification for referring centers, introduce patient support services at key HCM centers, and pilot the Association’s HCM detection algorithm to reduce underdiagnosis.
The initiative targets systemic barriers to more consistent, equitable care for the estimated one in 500 U.S. people living with HCM.
Cytokinetics (Nasdaq: CYTK) ha annunciato il 17 novembre 2025 il suo sostegno a un'iniziativa triennale dell'American Heart Association per migliorare diagnosi, accesso e trattamento per le persone che vivono con la cardiomiopatia ipertrofica (HCM).
L'azienda ha detto che sosterrà gli sforzi per espandere la partecipazione a un Registro nazionale HCM alimentato da Get With The Guidelines®, ampliare la certificazione per i centri di riferimento, introdurre servizi di supporto ai pazienti presso i principali centri HCM e piloterà l'algoritmo di rilevamento HCM dell'Associazione per ridurre la sottodiagnosi.
L'iniziativa mira a eliminare le barriere sistemiche per una cura più costante ed equa per circa una persona su 500 negli Stati Uniti che vive con HCM.
Cytokinetics (Nasdaq: CYTK) anunció el 17 de noviembre de 2025 su apoyo a una iniciativa de la American Heart Association de tres años para mejorar el diagnóstico, el acceso y el tratamiento de las personas que viven con miocardiopatía hipertrófica (HCM).
La empresa dijo que respaldará los esfuerzos para ampliar la participación en un Registro Nacional HCM impulsado por Get With The Guidelines®, ampliar la certificación para centros de derivación, introducir servicios de apoyo a los pacientes en centros clave de HCM y pilotar el algoritmo de detección de HCM de la Asociación para reducir el subdiagnóstico.
La iniciativa apunta a eliminar barreras sistémicas para una atención más constante y equitativa para aproximadamente una de cada 500 personas en EE. UU. que viven con HCM.
Cytokinetics (나스닥: CYTK) 은 2025년 11월 17일 미국심장협회(American Heart Association)의 3년간의 이니셔티브를 지지하겠다고 발표했습니다. 이 이니셔니브는 진단, 접근성 및 치료를 개선하기 위한 것으로, 고혈압성 심근병증(HCM)을 앓고 있는 이들을 대상으로 합니다.
회사은 Get With The Guidelines®가 운영하는 전국 HCM 등록부에 참여를 확대하고, 의뢰 센터의 인증을 확대하며, 주요 HCM 센터에서 환자 지원 서비스를 도입하고, 협회의 HCM 탐지 알고리즘을 파일럿해 과소진단을 줄이는 노력을 지지한다고 말했습니다.
이 이니셔티브는 미국 내 HCM으로 고통받는 약 1/500명의 더 일관되고 공평한 진료에 대한 체계적 장벽을 제거하는 것을 목표로 합니다.
Cytokinetics (Nasdaq : CYTK) a annoncé le 17 novembre 2025 son soutien à une initiative triennale de l'American Heart Association visant à améliorer le diagnostic, l'accès et le traitement des personnes atteintes de cardiomyopathie hypertrophique (HCM).
L'entreprise a déclaré qu'elle soutiendrait les efforts visant à élargir la participation à un registre national HCM alimenté par Get With The Guidelines®, à étendre la certification des centres référents, à mettre en place des services de soutien aux patients dans des centres HCM clés et à piloter l'algorithme de détection HCM de l'Association afin de réduire le sous-diagnostic.
L'initiative vise à s'attaquer aux barrières systémiques à des soins plus constants et équitables pour environ une personne sur 500 aux États-Unis vivant avec la HCM.
Cytokinetics (Nasdaq: CYTK) gab am 17. November 2025 seine Unterstützung für eine dreijährige Initiative der American Heart Association bekannt, die darauf abzielt, Diagnose, Zugang und Behandlung für Menschen mit hypertropher Cardiomyopathie (HCM) zu verbessern.
Das Unternehmen erklärte, es werde Anstrengungen unterstützen, die Teilnahme an einem nationalen HCM-Register zu erweitern, das von Get With The Guidelines® betrieben wird, die Zertifizierung für verweisende Zentren zu erweitern, Patientenunterstützungsdienste an wichtigen HCM-Zentren einzuführen und den Erkennungsalgorithmus der HCM der Vereinigung zu pilotieren, um Unterdiagnosen zu reduzieren.
Die Initiative zielt darauf ab, systemische Barrieren für eine konsistentere, gerechtere Versorgung der geschätzten eine von 500 US-Bürgern mit HCM abzubauen.
Cytokinetics (ناسداك: CYTK) أعلنت في 17 نوفمبر 2025 عن دعمها لمبادرة مدتها ثلاث سنوات من جمعية القلب الأمريكية تهدف إلى تحسين التشخيص والوصول إلى العلاج للأشخاص المصابين بتضخم عضلة القلب التسممي hypertrophic cardiomyopathy (HCM).
قالت الشركة إنها ستدعم الجهود لتوسيع المشاركة في سجل HCM الوطني الذي تديره Get With The Guidelines®، وتوسيع الاعتماد للمراكز المُرسِلة، وتقديم خدمات دعم المرضى في مراكز HCM الرئيسية، وتجربة خوارزمية الكشف عن HCM التابعة للجمعية لتقليل حالات التشخيص الناقص.
تستهدف المبادرة إزالة العوائق النظامية أمام رعاية أكثر اتساقاً وعدلاً للبالغين المصابين بـ HCM الذين يُقدَّر عددهم بنحو واحد من كل 500 في الولايات المتحدة.
- None.
- None.
Insights
Cytokinetics funds and partners with the American Heart Association to improve HCM diagnosis, care access, and registry participation.
The company will support a three-year American Heart Association initiative to address underdiagnosis and disparities in hypertrophic cardiomyopathy (HCM) care by expanding registry participation, certification for referring centers, patient support services, and a pilot of an HCM detection algorithm. This action reinforces Cytokinetics' ongoing engagement with the HCM community and aligns with its stated research and advocacy activities.
Key dependencies and risks include the initiative’s execution by the Association and participating sites, the measurable uptake of registry and certification activities, and the prospective pilot's ability to reduce underdiagnosis. Concrete items to watch are enrollment and geographic spread of sites in the national HCM Registry, launch and metrics from the detection-algorithm pilot, and any published interim outcomes over the next
System of Care to Advance Care for the Most Commonly Inherited Heart Disease
SOUTH SAN FRANCISCO, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) today announced its support of a three-year initiative led by the American Heart Association to address disparities in access to care, diagnosis, and treatment for people living with hypertrophic cardiomyopathy (HCM), a chronic and often underdiagnosed heart disease that affects hundreds of thousands of individuals across the United States. As a supporter of this multi-stakeholder undertaking, Cytokinetics will contribute its longstanding commitment to the HCM community to help close prevailing gaps between evidence, guidelines, implementation, and equity in healthcare delivery for HCM.
“Too many patients living with HCM face a lack of awareness about their condition, delayed diagnoses, and limited access to specialty care,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer. “We are proud to support the American Heart Association to advance a more standardized and comprehensive system of care. This important initiative aligns with our science and patient-centric company culture and reinforces our commitment to elevate the standard of care for those living with HCM.”
An estimated one in 500 people in the U.S. are living with HCM but many remain undiagnosed or untreated until acute symptoms occur. This underdiagnosis has led to inconsistent and fragmented systems of care. The American Heart Association initiative seeks to identify systemic barriers to improve HCM systems of care and improve how patients with HCM are identified, assessed, referred, and treated.
Cytokinetics’ support will build on a national effort to unify and elevate care for HCM patients by:
- increasing the number of sites participating in a national HCM Registry powered by Get With The Guidelines®;
- broadening certification opportunities for referring centers and personnel to reach more communities and patients;
- introducing patient support services at key HCM diagnosis and treatment centers; and
- implementing a prospective pilot of the Association’s HCM detection algorithm designed to reduce underdiagnosis.
“Cytokinetics’ participation underscores the importance of working across sectors to advance heart health,” said Anjali Owens, M.D., co-chair of the American Heart Association’s HCM initiative. “HCM is often inconsistently managed, leading to delayed treatment, increased risk of complications and preventable death. With this added support, we will work to drive meaningful change that empowers patients, informs clinicians, and strengthens the care continuum for HCM.”
Cytokinetics has been at the forefront of HCM-related research and advocacy activities. In addition to its investigational therapies for HCM and other cardiovascular conditions, the company actively collaborates with patient advocacy organizations, clinicians, and policymakers to enhance disease awareness and improve care pathways.
To learn more about Cytokinetics’ commitment to the HCM community, visit www.cytokinetics.com. To learn more about the initiative, visit www.heart.org/HCMregistry.
About Cytokinetics
Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics is readying for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor, following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. In addition, Cytokinetics is developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), ulacamten, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.
Disclaimer
Aficamten, omecamtiv mecarbil, ulacamten and CK-089 are investigational medicines. They have not been approved nor determined to be safe or efficacious for any disease state or any indication by FDA or any other regulatory agency.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development activities of Cytokinetics’ product candidates. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics’ business outlines in Cytokinetics’ filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics’ actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757
FAQ
What did Cytokinetics (CYTK) announce on November 17, 2025 about HCM care?
How will Cytokinetics support the American Heart Association HCM initiative?
What is the timeline for Cytokinetics' support of the HCM initiative (CYTK)?
What specific registry will Cytokinetics help expand for HCM patients?
How does the initiative aim to reduce HCM underdiagnosis according to Cytokinetics?
Where can investors find more information about Cytokinetics' HCM efforts and the initiative?
